<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FDA Set to Approve First Regulatory T Cell Therapy | News That's Not Crap</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=IBM+Plex+Sans:wght@400;500;600;700&family=Instrument+Serif:ital@0;1&display=swap" rel="stylesheet">
    <style>
        :root {
            --wgac-brown: #a1512e;
            --wgac-green-light: #d7f6a4;
            --wgac-blue: #4368ff;
            --wgac-teal: #2dcb98;
            --wgac-coral: #e85d4c;
            --wgac-yellow: #f0c808;
            --wgac-purple: #7b68ee;
            --wgac-pink: #e84393;
            --cream: #faf9f6;
            --dark: #1a1a1a;
            --gray-100: #f5f4f2;
            --gray-200: #e8e6e3;
            --gray-400: #a09d98;
            --gray-600: #6b6761;
            --font-display: 'Instrument Serif', Georgia, serif;
            --font-body: 'IBM Plex Sans', -apple-system, BlinkMacSystemFont, sans-serif;
        }

        * { margin: 0; padding: 0; box-sizing: border-box; }

        body {
            font-family: var(--font-body);
            background: var(--cream);
            color: var(--dark);
            line-height: 1.6;
            -webkit-font-smoothing: antialiased;
        }

        a { color: inherit; text-decoration: none; }

        /* Header */
        .site-header {
            background: var(--dark);
            padding: 0;
            position: sticky;
            top: 0;
            z-index: 1000;
        }

        .header-top {
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 1.25rem 3rem;
            border-bottom: 1px solid rgba(255,255,255,0.1);
        }

        .logo {
            display: flex;
            align-items: stretch;
            font-family: var(--font-body);
            font-size: 1rem;
            font-weight: 800;
            text-decoration: none;
        }

        .logo-left {
            background: white;
            color: var(--dark);
            padding: 0.5rem 0.75rem;
            display: flex;
            align-items: center;
            letter-spacing: 0.5px;
        }

        .logo-right {
            background: var(--wgac-blue);
            color: white;
            padding: 0.5rem 0.75rem;
            display: flex;
            align-items: center;
            letter-spacing: 0.5px;
        }

        .header-date {
            color: var(--gray-400);
            font-size: 0.8rem;
            font-weight: 500;
            letter-spacing: 0.5px;
            text-transform: uppercase;
        }

        /* Navigation */
        .main-nav {
            display: flex;
            justify-content: center;
            gap: 2px;
            padding: 0.75rem 0;
            background: var(--dark);
        }

        .nav-link {
            font-size: 0.7rem;
            font-weight: 700;
            letter-spacing: 0.5px;
            text-transform: uppercase;
            padding: 0.5rem 1rem;
            transition: all 0.15s ease;
            background: rgba(255,255,255,0.1);
            color: white;
        }

        .nav-link:hover {
            background: white;
            color: var(--dark);
        }

        .nav-link.active {
            background: var(--wgac-blue);
            color: white;
        }

        /* Article Hero */
        .article-hero {
            position: relative;
            height: 70vh;
            min-height: 500px;
            max-height: 700px;
            overflow: hidden;
        }

        .article-hero img {
            width: 100%;
            height: 100%;
            object-fit: cover;
        }

        .article-hero-overlay {
            position: absolute;
            inset: 0;
            background: linear-gradient(to top, rgba(0,0,0,0.8) 0%, rgba(0,0,0,0.3) 50%, rgba(0,0,0,0.1) 100%);
        }

        .article-hero-content {
            position: absolute;
            bottom: 0;
            left: 0;
            right: 0;
            padding: 4rem;
            max-width: 900px;
            margin: 0 auto;
            text-align: center;
        }

        .article-tag {
            display: inline-block;
            background: var(--wgac-coral);
            color: white;
            padding: 0.35rem 0.75rem;
            font-weight: 700;
            font-size: 0.65rem;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 1.5rem;
        }

        .article-hero h1 {
            font-family: var(--font-display);
            font-size: clamp(2.5rem, 5vw, 3.5rem);
            font-weight: 400;
            line-height: 1.15;
            color: white;
            margin-bottom: 1.5rem;
        }

        .article-meta {
            color: rgba(255,255,255,0.7);
            font-size: 0.9rem;
        }

        .article-meta span { margin: 0 0.75rem; }

        /* Article Content */
        .article-content {
            max-width: 700px;
            margin: 0 auto;
            padding: 4rem 2rem;
        }

        .article-lead {
            font-size: 1.35rem;
            line-height: 1.7;
            color: var(--dark);
            margin-bottom: 2rem;
            font-weight: 400;
        }

        .article-body p {
            font-size: 1.1rem;
            line-height: 1.8;
            margin-bottom: 1.5rem;
            color: var(--gray-600);
        }

        .article-body h2 {
            font-family: var(--font-display);
            font-size: 1.75rem;
            margin: 3rem 0 1.5rem;
            color: var(--dark);
        }

        .article-body blockquote {
            border-left: 3px solid var(--wgac-coral);
            padding-left: 1.5rem;
            margin: 2rem 0;
            font-family: var(--font-display);
            font-size: 1.4rem;
            font-style: italic;
            color: var(--dark);
        }

        /* Stats Box */
        .stats-box {
            background: var(--wgac-coral);
            color: white;
            padding: 2.5rem;
            margin: 3rem 0;
        }

        .stats-box h3 {
            font-family: var(--font-display);
            font-size: 1.25rem;
            margin-bottom: 1.5rem;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 2rem;
        }

        .stat-item { text-align: center; }

        .stat-number {
            font-family: var(--font-display);
            font-size: 3rem;
            line-height: 1;
            margin-bottom: 0.5rem;
        }

        .stat-label {
            font-size: 0.8rem;
            opacity: 0.9;
        }

        /* Image with caption */
        .article-figure {
            margin: 3rem -4rem;
        }

        .article-figure img {
            width: 100%;
            display: block;
        }

        .article-figure figcaption {
            font-size: 0.85rem;
            color: var(--gray-400);
            padding: 1rem 4rem;
            text-align: center;
        }

        .sources-box {
            margin-top: 3rem;
            padding: 2rem;
            background: var(--gray-100);
            border-left: 4px solid var(--wgac-coral);
        }

        .sources-box h3 {
            font-family: var(--font-body);
            font-size: 0.8rem;
            font-weight: 700;
            text-transform: uppercase;
            letter-spacing: 1px;
            color: var(--gray-600);
            margin-bottom: 1rem;
        }

        .sources-box ul {
            list-style: none;
        }

        .sources-box li {
            margin-bottom: 0.5rem;
        }

        .sources-box a {
            color: var(--wgac-coral);
            font-size: 0.9rem;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: border-color 0.2s ease;
        }

        .sources-box a:hover {
            border-bottom-color: var(--wgac-coral);
        }

        /* Related Articles */
        .related-section {
            background: var(--gray-100);
            padding: 4rem 2rem;
            margin-top: 4rem;
        }

        .related-inner {
            max-width: 1200px;
            margin: 0 auto;
        }

        .related-title {
            font-family: var(--font-display);
            font-size: 1.5rem;
            margin-bottom: 2rem;
            padding-bottom: 1rem;
            border-bottom: 2px solid var(--dark);
        }

        .related-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 2rem;
        }

        .related-card {
            background: white;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .related-card:hover { background: var(--cream); }
        .related-card:hover h4 { color: var(--wgac-brown); }

        .related-card img {
            width: 100%;
            height: 180px;
            object-fit: cover;
            display: block;
        }

        .related-card-content {
            padding: 1.25rem;
        }

        .related-card h4 {
            font-family: var(--font-display);
            font-size: 1.1rem;
            line-height: 1.35;
            transition: color 0.2s ease;
        }

        /* Footer */
        .site-footer {
            background: var(--dark);
            color: white;
            padding: 4rem 3rem;
        }

        .footer-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: flex-start;
        }

        .footer-brand {
            max-width: 350px;
        }

        .footer-logo {
            display: flex;
            align-items: stretch;
            font-family: var(--font-body);
            font-size: 0.85rem;
            font-weight: 800;
            margin-bottom: 1rem;
            width: fit-content;
        }

        .footer-logo .logo-left {
            background: white;
            color: var(--dark);
            padding: 0.4rem 0.6rem;
        }

        .footer-logo .logo-right {
            background: var(--wgac-blue);
            color: white;
            padding: 0.4rem 0.6rem;
        }

        .footer-tagline {
            font-size: 0.9rem;
            color: var(--gray-400);
            line-height: 1.6;
        }

        .footer-nav {
            display: flex;
            gap: 4rem;
        }

        .footer-col h4 {
            font-size: 0.7rem;
            font-weight: 700;
            letter-spacing: 1px;
            text-transform: uppercase;
            color: var(--gray-400);
            margin-bottom: 1rem;
        }

        .footer-col ul {
            list-style: none;
        }

        .footer-col li {
            margin-bottom: 0.5rem;
        }

        .footer-col a {
            font-size: 0.9rem;
            color: white;
            opacity: 0.8;
            transition: opacity 0.2s ease;
        }

        .footer-col a:hover {
            opacity: 1;
        }

        .footer-bottom {
            max-width: 1400px;
            margin: 3rem auto 0;
            padding-top: 2rem;
            border-top: 1px solid rgba(255,255,255,0.1);
            font-size: 0.8rem;
            color: var(--gray-400);
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .footer-update {
            font-size: 0.7rem;
            opacity: 0.6;
            letter-spacing: 0.5px;
        }

        /* Responsive */
        @media (max-width: 1024px) {
            .related-grid {
                grid-template-columns: 1fr;
            }
            .footer-content {
                flex-direction: column;
                gap: 3rem;
            }
        }

        @media (max-width: 768px) {
            .header-top { padding: 1rem 1.5rem; }
            .main-nav { flex-wrap: wrap; }
            .nav-link { padding: 0.75rem 1rem; font-size: 0.7rem; }
            .article-hero-content { padding: 2rem 1.5rem; }
            .article-content { padding: 2rem 1.5rem; }
            .article-figure { margin: 2rem -1.5rem; }
            .article-figure figcaption { padding: 1rem 1.5rem; }
            .stats-grid { grid-template-columns: 1fr; gap: 1.5rem; }
        }
    </style>
</head>
<body>
    <!-- Header -->
    <header class="site-header">
        <div class="header-top">
            <a href="../index.html" class="logo"><span class="logo-left">NEWS THAT'S NOT</span><span class="logo-right">CRAP</span></a>
            <div class="header-date">Wednesday, January 29, 2026</div>
        </div>
        <nav class="main-nav">
            <a href="../index.html" class="nav-link">Today</a>
            <a href="../climate.html" class="nav-link">Climate</a>
            <a href="../health.html" class="nav-link active">Health</a>
            <a href="../science.html" class="nav-link">Science</a>
            <a href="../people.html" class="nav-link">People</a>
            <a href="../wildlife.html" class="nav-link">Wildlife</a>
            <a href="../cats.html" class="nav-link">Cats</a>
        </nav>
    </header>

    <!-- Article Hero -->
    <div class="article-hero">
        <img src="https://images.unsplash.com/photo-1579154204601-01588f351e67?w=1920&q=80" alt="Laboratory research with microscope">
        <div class="article-hero-overlay"></div>
        <div class="article-hero-content">
            <span class="article-tag">Health</span>
            <h1>FDA Set to Approve First Regulatory T Cell Therapy</h1>
            <div class="article-meta">
                <span>By Reggie Lator</span>
                <span>·</span>
                <span>January 29, 2026</span>
                <span>·</span>
                <span>6 min read</span>
            </div>
        </div>
    </div>

    <!-- Article Content -->
    <article class="article-content">
        <p class="article-lead">
            What do lupus, stiff person syndrome, systemic sclerosis, and transplant rejection have in common? They're all caused by your immune system attacking things it shouldn't. And after decades of research, we're on the verge of the first FDA-approved CAR-T and regulatory T cell therapies for autoimmune disease.
        </p>

        <div class="article-body">
            <p>
                Kyverna Therapeutics announced positive topline data from their registrational KYSA-8 trial that could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease. The company is on track to submit a Biologics License Application (BLA) for stiff person syndrome in the first half of 2026.
            </p>

            <p>
                Meanwhile, Sonoma Biotherapeutics reported interim Phase 1 data for their CAR Treg therapy targeting refractory rheumatoid arthritis, demonstrating favorable safety and early signs of clinical activity. This isn't just a new drug—it's an entirely new category of treatment that could transform how we handle autoimmune diseases.
            </p>

            <blockquote>
                "For the first time, we're not just suppressing the immune system—we're re-educating it. Teaching it tolerance rather than beating it into submission."
            </blockquote>

            <p>
                Regulatory T cells are your body's natural peacekeepers. They're a specialized subset of immune cells whose job is to prevent other immune cells from attacking healthy tissue. In autoimmune diseases, these regulators are either outnumbered, outgunned, or just not doing their jobs properly.
            </p>

            <div class="stats-box">
                <h3>By The Numbers</h3>
                <div class="stats-grid">
                    <div class="stat-item">
                        <div class="stat-number">24M</div>
                        <div class="stat-label">Americans with autoimmune diseases</div>
                    </div>
                    <div class="stat-item">
                        <div class="stat-number">94%</div>
                        <div class="stat-label">Bristol Myers patients off immunosuppression</div>
                    </div>
                    <div class="stat-item">
                        <div class="stat-number">80+</div>
                        <div class="stat-label">Known autoimmune conditions</div>
                    </div>
                </div>
            </div>

            <h2>CAR-T for Autoimmune Disease: A New Frontier</h2>

            <p>
                Bristol Myers Squibb presented positive early results from their Phase 1 Breakfree-1 study of CD19 NEX-T CAR T cell therapy at ACR Convergence 2025. The data evaluated 71 treated patients across systemic sclerosis, systemic lupus erythematosus, and idiopathic inflammatory myopathies cohorts, with 94% of evaluable patients remaining off chronic immunosuppressive therapy.
            </p>

            <p>
                Kyverna's miv-cel therapy for stiff person syndrome achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose, with no high-grade cytokine release syndrome or neurotoxicity observed. The therapy has received both Regenerative Medicine Advanced Therapy and Orphan Drug designations from the FDA.
            </p>

            <p>
                In January 2025, the FDA cleared Allogene Therapeutics' IND application for ALLO-329, an investigational allogeneic CAR T product. The Phase 1 RESOLUTION basket trial will evaluate safety and efficacy in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
            </p>

            <figure class="article-figure">
                <img src="https://images.unsplash.com/photo-1582719471384-894fbb16e074?w=1400&q=80" alt="Medical laboratory equipment">
                <figcaption>CAR-T cell manufacturing involves genetically modifying a patient's T cells to target specific disease markers. Photo: Kyverna Therapeutics</figcaption>
            </figure>

            <h2>Regulatory T Cell Therapies Advance</h2>

            <p>
                Quell Therapeutics' QEL-001, a CAR Treg product, is being tested in an ongoing Phase 1/2 trial to induce immune tolerance in HLA-A2 mismatched liver transplant patients. Initial safety data showed that CAR Tregs were successfully infused without serious adverse events, with evidence of cell engraftment and homing to the transplanted organ.
            </p>

            <p>
                At the end of October 2025, Sonoma Biotherapeutics reported interim Phase 1 data for SBT-77-7101, an autologous CAR Treg specific for citrullinated proteins in refractory rheumatoid arthritis. CK0803, a next-generation off-the-shelf Treg product engineered to express CNS homing markers, was granted Orphan Drug Designation by the FDA for the treatment of ALS.
            </p>

            <p>
                "The beautiful thing is we're using the body's own machinery," researchers explain. "We're not introducing anything foreign. We're just boosting or redirecting what's already there."
            </p>

            <h2>The Path to Approval</h2>

            <p>
                Current CAR-T trials for autoimmune rheumatic diseases are limited by small sample sizes (6-75 participants) and single-center designs, but the FDA's breakthrough therapy designation may facilitate accelerated clinical translation of these therapies.
            </p>

            <p>
                Manufacturing personalized cell therapies remains expensive and complex. The current process takes about two weeks and can cost upwards of $200,000 per treatment. That's a problem when 24 million Americans have autoimmune diseases.
            </p>

            <p>
                For now, though, the progress represents hope for conditions that have had few treatment advances in decades. With Kyverna's BLA submission planned for early 2026, we may soon see the first approved cell therapy specifically for autoimmune disease.
            </p>

            <div class="sources-box">
                <h3>Sources</h3>
                <ul>
                    <li><a href="https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-announces-positive-topline-data" target="_blank">Kyverna Therapeutics: Positive Topline Data from KYSA-8 Trial</a></li>
                    <li><a href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Presents-Encouraging-Data-from-Phase-1-Breakfree-1-Study-of-CD19-NEX-T-CAR-T-Cell-Therapy-in-Three-Chronic-Autoimmune-Diseases-at-ACR-Convergence-2025/default.aspx" target="_blank">Bristol Myers Squibb: CD19 NEX-T CAR T Cell Therapy Data</a></li>
                    <li><a href="https://www.cell.com/cell/fulltext/S0092-8674(25)01370-4" target="_blank">Cell: Next Steps in Regulatory T Cells</a></li>
                    <li><a href="https://www.biospace.com/drug-development/5-car-t-cell-therapies-with-autoimmune-readouts-in-2025" target="_blank">BioSpace: 5 CAR T Cell Therapies With Autoimmune Readouts in 2025</a></li>
                </ul>
            </div>
        </div>
    </article>

    <!-- Related Articles -->
    <section class="related-section">
        <div class="related-inner">
            <h2 class="related-title">More Health Stories</h2>
            <div class="related-grid">
                <a href="rsv-decline.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1584515933487-779824d29309?w=600&q=80" alt="Infant with parent">
                    <div class="related-card-content">
                        <h4>RSV Hospitalizations Plummet Thanks to New Vaccines</h4>
                    </div>
                </a>
                <a href="malaria-vaccine.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1584036561566-baf8f5f1b144?w=600&q=80" alt="Vaccine">
                    <div class="related-card-content">
                        <h4>Malaria Vaccine Reaches 1 Million African Children</h4>
                    </div>
                </a>
                <a href="cancer-detection.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1576671081837-49000212a370?w=600&q=80" alt="Medical research">
                    <div class="related-card-content">
                        <h4>Blood Test Can Now Detect 50 Types of Cancer Early</h4>
                    </div>
                </a>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-brand">
                <div class="footer-logo"><span class="logo-left">NEWS THAT'S NOT</span><span class="logo-right">CRAP</span></div>
                <p class="footer-tagline">Doom-scrolling is so last decade. We bring you the breakthroughs, the victories, and the genuinely good stuff happening in the world.</p>
            </div>
            <nav class="footer-nav">
                <div class="footer-col">
                    <h4>Sections</h4>
                    <ul>
                        <li><a href="../climate.html">Climate</a></li>
                        <li><a href="../health.html">Health</a></li>
                        <li><a href="../science.html">Science</a></li>
                        <li><a href="../people.html">People</a></li>
                        <li><a href="../wildlife.html">Wildlife</a></li>
                        <li><a href="../cats.html">Cats</a></li>
                    </ul>
                </div>
                <div class="footer-col">
                    <h4>About</h4>
                    <ul>
                        <li><a href="../mission.html">Our Mission</a></li>
                        <li><a href="../team.html">Team</a></li>
                        <li><a href="../contact.html">Contact</a></li>
                    </ul>
                </div>
            </nav>
        </div>
        <div class="footer-bottom">
            <span>© 2026 News That's Not Crap. All the good vibes reserved.</span>
            <span class="footer-update">Updated daily at 6am Eastern</span>
        </div>
    </footer>
</body>
</html>
